Publicacións en colaboración con investigadores/as de University of Oxford (11)

2021

  1. Acriflavine, a potent inhibitor of HIF-1α, disturbs glucose metabolism and suppresses ATF4-protective pathways in melanoma under non-hypoxic conditions

    Cancers, Vol. 13, Núm. 1, pp. 1-17

  2. BRN2 is a non-canonical melanoma tumor-suppressor

    Nature Communications, Vol. 12, Núm. 1

  3. MITF induces escape from innate immunity in melanoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

2017

  1. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma

    Genes and Development, Vol. 31, Núm. 1, pp. 18-33

2016

  1. Targeting the epigenetics of the DNA damage response in breast cancer

    Cell Death and Disease, Vol. 7

  2. Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis

    Oncogene, Vol. 35, Núm. 47, pp. 6143-6152

2015

  1. MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma

    Pigment Cell and Melanoma Research, Vol. 28, Núm. 6, pp. 736-740

  2. Targeting the epigenetic machinery of cancer cells

    Oncogene, Vol. 34, Núm. 2, pp. 135-143

2013

  1. Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, Núm. 29, pp. 11893-11898

  2. Directed Phenotype Switching as an Effective Antimelanoma Strategy

    Cancer Cell, Vol. 24, Núm. 1, pp. 105-119

2012

  1. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance

    Experimental Cell Research, Vol. 318, Núm. 10, pp. 1146-1159